Intellia Therapeutics, Inc. (NTLA) director purchases 150,000 shares

Rhea-AI Filing Summary

Intellia Therapeutics, Inc. director Fred E. Cohen reported an open market purchase of the company’s common stock. On January 5, 2026, he bought 150,000 shares of common stock at a weighted average price of $9.35 per share, coded as a purchase transaction.

According to the filing, these shares were acquired in multiple trades at prices ranging from $9.13 to $9.68. Following this transaction, Cohen beneficially owns 207,453 shares of Intellia Therapeutics common stock held directly.

Insider Trade Summary

Net Buyer: 150,000 shares

Net Buy 1 txn

Insider Cohen Fred E

Role Director

Bought 150,000 shs ($1.40M)

Type	Security	Shares	Price	Value
Purchase	Common Stock	150,000	$9.35	$1.40M

Holdings After Transaction: Common Stock — 207,453 shares (Direct)

Footnotes (2)

1. F1. Reflects an open market purchase of shares of the Issuer's common stock by the Reporting Person in accordance with the Issuer's trading policies.
2. F2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.13 to $9.68, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares purchased by the reporting person on January 5, 2026 at each separate price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 01/07/2026 - 04:05 PM Learn about SEC filing dates

FAQ

What insider transaction was reported for Intellia Therapeutics (NTLA)?

Intellia Therapeutics reported that director Fred E. Cohen purchased 150,000 shares of its common stock in an open market transaction on January 5, 2026.

Who is the insider involved in the latest Intellia Therapeutics (NTLA) Form 4 filing?

The insider is Fred E. Cohen, a director of Intellia Therapeutics, Inc., as disclosed in the Form 4.

How many Intellia Therapeutics (NTLA) shares did the director buy and at what price?

Director Fred E. Cohen bought 150,000 shares of Intellia Therapeutics common stock at a weighted average price of $9.35 per share, with individual trades executed between $9.13 and $9.68.

How many Intellia Therapeutics (NTLA) shares does Fred E. Cohen own after this transaction?

After the reported purchase, Fred E. Cohen beneficially owns 207,453 shares of Intellia Therapeutics common stock held directly.

Was the Intellia Therapeutics (NTLA) director trade an open market purchase?

Yes. A footnote explains that the transaction reflects an open market purchase of Intellia Therapeutics common stock by the reporting person in accordance with the company’s trading policies.

How were the purchase prices for the Intellia Therapeutics (NTLA) director trade distributed?

The filing states that the $9.35 price is a weighted average, with multiple transactions executed at prices ranging from $9.13 to $9.68 per share.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cohen Fred E

(Last) (First) (Middle)

C/O INTELLIA THERAPEUTICS, INC.

40 ERIE STREET; SUITE 130

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Intellia Therapeutics, Inc. [ NTLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/05/2026		P(1)		150,000	A	$9.35(2)	207,453	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects an open market purchase of shares of the Issuer's common stock by the Reporting Person in accordance with the Issuer's trading policies.

2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.13 to $9.68, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares purchased by the reporting person on January 5, 2026 at each separate price.

	/s/ James Basta, attorney-in-fact	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.